文献速递神经肿瘤

CD155调控弥漫性中线胶质瘤生长及T细胞杀伤敏感性

CD155 regulates tumor growth and susceptibility to T cell mediated killing in diffuse midline glioma.
PubMed 文献 · Neuro Oncol · 2026-08-10

本研究在弥漫性中线胶质瘤(DMG)中筛选免疫检查点分子,发现CD155表达最高;沉默CD155可增强CD8+ T细胞杀伤、诱导肿瘤细胞凋亡并延缓肿瘤生长,其作用经FOXM1介导,FOXM1靶向药Thiostrepton可延长荷瘤小鼠生存。

要点

  • CD155是DMG中表达最高的免疫检查点分子。
  • 沉默CD155增强CD8+ T细胞杀伤并诱导DMG细胞凋亡。
  • Thiostrepton靶向FOXM1可延缓DMG生长并延长生存。

核心结论

  • CD155调控DMG的免疫逃逸和肿瘤生长,靶向CD155可能成为双向治疗策略。

研究设计与样本

  • 在人和小鼠DMG细胞及原发脑肿瘤样本中筛选免疫检查点分子。
  • 采用共培养实验和体内免疫细胞清除评估检查点靶向的免疫反应。
  • 通过全转录组分析研究CD155沉默效应,并进行Thiostrepton体内治疗实验。

主要发现

  • CD155是人和小鼠DMG细胞及原发脑肿瘤样本中表达最高的免疫检查点。
  • 小鼠DMG细胞与CD8+ T细胞共培养时,沉默CD155显著增加T细胞介导的杀伤。
  • CD155缺陷DMG细胞在免疫健全小鼠中不能生长,清除CD8+ T细胞后肿瘤可生长。
  • 沉默CD155诱导DMG细胞凋亡并延缓免疫缺陷小鼠肿瘤生长。
  • 转录组分析确定FOXM1为CD155关键靶点,沉默FOXM1减少DMG细胞体外和体内增殖。

临床怎么用

  • CD155可作为DMG潜在免疫治疗靶点,兼具增强免疫杀伤和直接抗肿瘤作用。
  • FOXM1靶向药物Thiostrepton在动物模型中显示治疗潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diffuse midline glioma (DMG) is a devastating pediatric brain tumor with an unmet need for novel therapies. Immune checkpoint inhibitors have failed to prolong survival of DMG patients. METHODS: In this study, we screened for immune checkpoint molecules in DMG, evaluated immunological responses to checkpoint targeting by co-culture assays and depletion of immune cells in vivo, studied the effects of CD155 silencing by whole-transcriptome analyses and performed in vivo treatments with Thiostrepton. RESULTS: In human and murine DMG cells, as well as primary brain tumor samples, we identified CD155 as the most highly expressed immune checkpoint. When murine DMG cells were co-cultured with CD8+ T cells, silencing of CD155 led to a marked increase in T cell-mediated killing. Strikingly, CD155-deficient DMG cells failed to grow in immunocompetent mice, and depletion of CD8+ T cells allowed these tumors to grow. CD155 also exerted cell-autonomous effects on tumor cells: silencing of CD155 led to induction of apoptosis of DMG cells and delayed tumor growth in immunodeficient mice. Transcriptomic analyses identified FOXM1 as a key target of CD155. Notably, FOXM1 silencing also led to reduced proliferation of DMG cells in vitro and in vivo. Finally, treatment of DMG-bearing mice with Thiostrepton, a FOXM1-targeting agent, delayed tumor growth and prolonged survival. CONCLUSIONS: These studies demonstrate that CD155 regulates immune evasion and tumor growth in DMG, and suggest that targeting CD155 could be a valuable two-pronged therapeutic strategy for this disease. Diffuse midline glioma (DMG) is the deadliest pediatric brain tumor and novel therapies are urgently needed. Immunotherapy has failed to improve survival for these patients. We propose that one reason is the low expression of previously targeted immune-checkpoint molecules, and introduce CD155 as a highly expressed molecule across DMG and other brain tumors. Excitingly, we discover that blocking CD155 not only improves anti-tumor immune responses, but also directly kills tumor cells. Finally, we uncover FOXM1 as a target of CD155 and show that the FOXM1-targeting agent Thiostrepton prolongs survival of DMG-bearing mice, thereby introducing a novel therapeutic strategy for DMG.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Tzaridis T, Fernández EC, Eisemann T, et al. CD155 regulates tumor growth and susceptibility to T cell mediated killing in diffuse midline glioma. Neuro Oncol. 2026. PMID: 42573567. doi:10.1093/neuonc/noag178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。